| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BCL2 like 12; BCL2L12; BPR;;Bcl 2 L12 |
| WB Predicted band size | Calculated MW: 37 kDa ; Observed MW: 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Bcl 2 L12 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于BCL2L12抗体的3篇代表性文献摘要(示例基于公开研究主题，具体作者和标题为虚构示例，建议通过学术数据库核实真实文献)：
---
1. **文献名称**：*BCL2L12 Expression in Glioblastoma: Prognostic Implications and Interaction with p53*
**作者**：Stegh AH, et al.
**摘要**：该研究通过免疫组化(使用BCL2L12特异性抗体)分析胶质母细胞瘤样本，发现BCL2L12高表达与患者生存期缩短相关，并揭示其通过抑制p53依赖性凋亡通路促进肿瘤进展。
2. **文献名称**：*BCL2L12 as a Novel Biomarker in Triple-Negative Breast Cancer*
**作者**：Floros KV, et al.
**摘要**：研究利用Western blot和免疫荧光(基于BCL2L12抗体)检测三阴性乳腺癌组织，证实BCL2L12在细胞质/核异常表达与化疗耐药性相关，提示其可作为潜在治疗靶点。
3. **文献名称**：*BCL2L12 Antibody-Based Detection in Colorectal Cancer: Diagnostic Utility*
**作者**：Papadakis ES, et al.
**摘要**：通过ELISA和免疫组化评估结直肠癌患者血清及组织中的BCL2L12水平，发现其高表达与转移风险增加相关，支持BCL2L12抗体在临床诊断中的应用价值。
---
**建议**：通过PubMed或Google Scholar检索“BCL2L12 antibody”、“BCL2L12 cancer”等关键词，筛选涉及抗体实验(如IHC、WB)的文献以获取真实参考文献。
The BCL2L12 (B-cell lymphoma 2-like 12) gene encodes a member of the BCL-2 protein family, which plays critical roles in regulating apoptosis, cellular homeostasis, and stress responses. Unlike classical BCL-2 family members, BCL2L12 contains a unique C-terminal domain rich in proline residues and lacks a transmembrane region, suggesting distinct functional mechanisms. It exhibits dual roles in apoptosis, acting as either a pro-apoptotic or anti-apoptotic protein depending on cellular context, post-translational modifications, and interaction partners. BCL2L12 is highly expressed in certain cancers, including glioblastoma, colorectal carcinoma, and breast cancer, where it often correlates with tumor progression, therapy resistance, and poor prognosis. In glioblastoma, for instance, BCL2L12 inhibits apoptosis by sequestering p53 or caspase-7 while promoting cell cycle arrest, contributing to therapeutic evasion.
Antibodies targeting BCL2L12 are essential tools for studying its expression patterns, subcellular localization (cytosolic and nuclear), and functional interactions in both physiological and pathological states. These antibodies—often monoclonal or polyclonal—are validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Their development has enabled the identification of BCL2L12 as a potential biomarker for cancer diagnosis and prognosis. Notably, BCL2L12 antibodies have been instrumental in revealing its post-transcriptional regulation by microRNAs and its role in modulating chemoresistance pathways. Ongoing research focuses on leveraging these antibodies to explore BCL2L12-targeted therapies, particularly in malignancies where its dysregulation drives tumor aggressiveness.
×
